Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
codergocrine mesylate
- Development stage
- Unknown
- Lead developer
- Sandoz
- Modality
- Small Molecules
- Administration
- Oral, Sublingual
01
Overview
Codergocrine mesylate (also known as dihydroergotoxine mesylate or ergoloid mesylates) is a small-molecule mixture of the methanesulfonate salts of four dihydrogenated ergot alkaloids: dihydroergocornine, dihydroergocristine, and alpha- and beta-dihydroergocryptine. Originally developed by Albert Hofmann at Sandoz (now Novartis), it acts as a multi-receptor modulator with affinity for dopaminergic, serotonergic, and alpha-adrenergic receptors, as well as the GABA-A receptor chloride channel. It is primarily used to treat symptoms of age-related cognitive decline, dementia (including Alzheimer's and vascular dementia), and cerebrovascular insufficiency. The drug is thought to improve cerebral metabolism and oxygen uptake while centrally decreasing vascular tone through alpha-adrenoceptor blockade.
- Brand names
- HydergineXidezhenRederginHydergina
- Other names
- dihydroergotoxine mesylateergoloid mesylateshydergotoxine mesylate
02
Targets
DRD2 (Dopamine D2 Receptor)ADRA1A (α1A)ADRA2A (α2A)DRD1 (Dopamine D1 Receptor)5-HT1R (5-HT1 receptor family)5-HT2 (5-HT2 receptor family)
Beyond the preview
Go deeper on codergocrine mesylate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on codergocrine mesylate.